Find recruiting clinical trials for mesothelioma in the UK — including mesothelin-targeted CAR-T cell therapy, bispecific antibodies, the SELECTmeso platform trial, and novel immunotherapy combinations for pleural and peritoneal disease. See your treatment pathway and where trials fit in.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Epithelioid subtype, good performance status, resectable disease
Standard: Extended pleurectomy decortication (PD) or extrapleural pneumonectomy (EPP), with neoadjuvant/adjuvant chemotherapy
Advanced disease not suitable for surgery
Standard: Pemetrexed + cisplatin (or carboplatin), nivolumab + ipilimumab for non-epithelioid subtypes
Disease progression after first-line treatment
Standard: Clinical trial enrollment recommended; SELECTmeso platform trial; vinorelbine palliative chemotherapy
Rarer form affecting abdominal lining
Standard: Cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC), systemic chemotherapy
A UK multicentre, multi-arm, adaptive phase II platform trial at the University of Southampton. Tests multiple targeted therapies in molecularly stratified cohorts of relapsed mesothelioma. A pioneering example of precision oncology in a rare cancer.
CAR-T cell therapy targeting mesothelin, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates directed at this cell-surface protein highly expressed on mesothelioma cells. Early-phase trials show encouraging results.
Trials testing bispecific PD-1/VEGF antibodies, LAG-3 inhibitors, and anti-TIGIT agents — aiming to overcome resistance to current checkpoint blockade in mesothelioma.
Trials investigating heated intraoperative chemotherapy (HIOC) after pleurectomy decortication, photodynamic therapy as an adjunct to surgery, and optimised radiotherapy techniques for pain control.
Loading trials from ClinicalTrials.gov...
SELECTmeso is a UK multicentre, adaptive phase II platform trial for relapsed malignant mesothelioma. It tests multiple targeted therapies in molecularly stratified subgroups. Recruitment is via participating NHS hospitals.
Yes. Early-phase trials are testing CAR-T cells targeting mesothelin — a protein highly expressed on mesothelioma cells. These are mostly at specialist centres and have strict eligibility criteria.
Pleural mesothelioma (lung lining) is more common and has more trial options. Peritoneal mesothelioma (abdominal lining) is rarer — trials often involve heated intraperitoneal chemotherapy (HIPEC) combined with novel agents.
Nivolumab + ipilimumab is now approved for mesothelioma, but trials are testing the next wave — including bispecific antibodies, novel checkpoint inhibitors, and combinations with mesothelin-targeted agents.
Use our search above to find trials matching your condition and location. Review eligibility criteria carefully.
Talk to your GP or oncologist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.